New data support CAR-T therapy in neuroinflammatory diseases
Drug Discovery World
SEPTEMBER 20, 2024
Kyverna Therapeutics has revealed continued positive results for its CAR-T therapy KYV-101 in B cell-driven autoimmune diseases. The case reports demonstrate disease modification across trials and durability in some patients extending beyond one year and a well-tolerated safety profile.
Let's personalize your content